Direct oral anticoagulants for the treatment of cerebral venous thrombosis – a protocol of an international phase IV study

INTRODUCTION: Current guidelines recommend that patients with cerebral venous thrombosis (CVT) should be treated with vitamin K antagonists (VKAs) for 3–12 months. Direct oral anticoagulants (DOACs), however, are increasingly used in clinical practice. An exploratory randomized controlled trial incl...

Descripción completa

Detalles Bibliográficos
Autores principales: van de Munckhof, Anita, Sánchez van Kammen, Mayte, Krzywicka, Katarzyna, Aaron, Sanjith, Aguiar de Sousa, Diana, Antochi, Florina, Arauz, Antonio, Barboza, Miguel A., Conforto, Adriana B., Dentali, Francesco, Galdames Contreras, Daniel, Ji, Xunming, Jood, Katarina, Heldner, Mirjam R., Hernández-Pérez, María, Kam, Wayneho, Kleinig, Timothy J., Kristoffersen, Espen S., Leker, Ronen R., Lemmens, Robin, Poli, Sven, Yeşilot, Nilüfer, Wasay, Mohammad, Wu, Teddy Y., Arnold, Marcel, Lucas-Neto, Lia, Middeldorp, Saskia, Putaala, Jukka, Tatlisumak, Turgut, Ferro, José M., Coutinho, Jonathan M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10539579/
https://www.ncbi.nlm.nih.gov/pubmed/37780701
http://dx.doi.org/10.3389/fneur.2023.1251581

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10539579/
https://www.ncbi.nlm.nih.gov/pubmed/37780701
http://dx.doi.org/10.3389/fneur.2023.1251581

Ejemplares similares